RAPP
Rapport Therapeutics, Inc.
$38.40
+9.06%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$789.9M
Inst. Activity11 buys / 4 sells
Insider Activity0B / 13S
Insider Net $-$36.5M
SEC Reports8
Press Releases3
Recent Activity
Jun 11, 2026
SEC
Three mega-passive institutional investors (Vanguard, BlackRock, Fidelity) collectively added $211.6M to their RAPP posi
INST-CLUSTER — Impact 3/10
Jun 10, 2026
Insider
MARAGANORE JOHN was granted 15,200 shares
Director
Jun 10, 2026
Insider
Sanchez Ramiro was granted 15,200 shares
Director
Jun 10, 2026
Insider
Young Wendy B. was granted 15,200 shares
Director
May 27, 2026
SEC
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 share
144 — Impact 5/10
May 20, 2026
other
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs
May 11, 2026
SEC
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 to sell 133,618 shares of Rapport Therapeutics common s
144 — Impact 5/10
Inst.
Polar Capital Holdings Plc — ADD
1,642,461 shares ($51.4M)
Price Targets
$57.10
+48.7% upside
Strong Buy
Current $38.40
Low $40.00
Median $56.00
High $80.00
10 analysts
$40.00
$80.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 21, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 8, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 22, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 11, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.00 ▼ -16.6% | $-1.04 — $-0.90 | -33% YoY | 6 |
| Next Q | $-1.00 ▼ -5.1% | $-1.07 — $-0.82 | -41% YoY | 6 |
| Current FY | $-3.47 ▼ -3.1% | $-3.67 — $-3.00 | -21% YoY | 6 |
| Next FY | $-4.47 ▼ -6.4% | $-5.89 — $-3.56 | -29% YoY | 7 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, BlackRock, Fidelity) collectively added $211.6M to their RAPP posi
Jun 11, 2026
BEARISH
144
5/10
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 share
May 27, 2026
BULLISH
Press
8/10
Rapport Therapeutics announced positive follow-up data from its Phase 2a trial of RAP-219 in focal onset seizures, showi
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $224.3M | ADD |
| Capital International Investors | $96.9M | ADD |
| GOLDMAN SACHS GROUP INC | $92.1M | — |
| BlackRock, Inc. | $78.4M | ADD |
| Polar Capital Holdings Plc | $51.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | MARAGANORE JOHN | A | $0.00 |
| Jun 10, 2026 | Sanchez Ramiro | A | $0.00 |
| Jun 10, 2026 | Young Wendy | A | $0.00 |
| Jun 10, 2026 | Huber Reid | A | $0.00 |
| Jun 10, 2026 | HEALY JAMES | A | $0.00 |
50 institutional holders with $789.9M total value (25,267,608 shares) as of 2026-Q1. Top holders: FMR, Capital, GOLDMAN. Net buying activity: 11 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 7,168,939 | $224.3M | 28.4% | ADD +26.3% |
| 2 | Capital International Investors | 3,097,973 | $96.9M | 12.3% | ADD +30.7% |
| 3 | GOLDMAN SACHS GROUP INC | 2,942,251 | $92.1M | 11.7% | — |
| 4 | BlackRock, Inc. | 2,505,955 | $78.4M | 9.9% | ADD +55.1% |
| 5 | Polar Capital Holdings Plc | 1,642,461 | $51.4M | 6.5% | ADD +63.5% |
| 6 | BAKER BROS. ADVISORS LP | 1,547,090 | $48.4M | 6.1% | DOUBLED +181.2% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1,325,082 | $41.5M | 5.2% | — |
| 8 | STATE STREET CORP | 759,552 | $23.8M | 3.0% | ADD +92.3% |
| 9 | ALLIANCEBERNSTEIN L.P. | 727,843 | $22.1M | 2.8% | NEW |
| 10 | Capital World Investors | 536,607 | $16.8M | 2.1% | NEW |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 320,909 | $10.0M | 1.3% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 239,917 | $7.5M | 1.0% | DOUBLED +116.5% |
| 13 | DIMENSIONAL FUND ADVISORS LP | 224,498 | $7.0M | 0.9% | DOUBLED +168.9% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 189,253 | $5.9M | 0.7% | — |
| 15 | D. E. Shaw & Co., Inc. | 175,449 | $5.5M | 0.7% | — |
| 16 | Invesco Ltd. | 171,757 | $5.4M | 0.7% | TRIM -35.7% |
| 17 | MORGAN STANLEY | 165,954 | $5.2M | 0.7% | DOUBLED +295.3% |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 150,000 | $4.7M | 0.6% | TRIM -66.7% |
| 19 | Freestone Grove Partners LP | 127,783 | $4.0M | 0.5% | — |
| 20 | PRUDENTIAL FINANCIAL INC | 114,815 | $3.6M | 0.5% | TRIM -55.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | ADD | 1,004,728 | 1,642,461 | +63.5% | $51.4M | 2026-Q1 |
| Capital World Investors | NEW | — | 536,607 | — | $16.8M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 83,487 | 224,498 | +168.9% | $7.0M | 2026-Q1 |
| Invesco Ltd. | TRIM | 267,120 | 171,757 | -35.7% | $5.4M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 254,967 | 114,815 | -55.0% | $3.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 34,553 | 110,826 | +220.7% | $3.5M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 56,457 | 78,231 | +38.6% | $2.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 2,282 | 32,918 | +1342.5% | $1.0M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 18,268 | 30,819 | +68.7% | $964.3K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 8,297 | 23,914 | +188.2% | $748.3K | 2026-Q1 |
| Trexquant Investment LP | TRIM | 62,979 | 20,984 | -66.7% | $656.6K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 118,814 | 9,700 | -91.8% | $303.5K | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 6,823 | 9,023 | +32.2% | $282.3K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 420 | 582 | +38.6% | $18.2K | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 55 | 143 | +160.0% | $4.5K | 2026-Q1 |
| BlackRock, Inc. | ADD | 1,568,081 | 2,431,862 | +55.1% | $73.8M | 2025-Q4 |
| ALLIANCEBERNSTEIN L.P. | NEW | — | 788,411 | — | $23.9M | 2025-Q4 |
| STATE STREET CORP | ADD | 371,626 | 714,821 | +92.3% | $21.7M | 2025-Q4 |
| Invesco Ltd. | ADD | 157,984 | 267,120 | +69.1% | $8.1M | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 450,000 | 150,000 | -66.7% | $4.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 35,300 | 118,814 | +236.6% | $3.6M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 11,330 | 83,487 | +636.9% | $2.5M | 2025-Q4 |
| Nuveen, LLC | DOUBLED | 21,873 | 70,946 | +224.4% | $2.2M | 2025-Q4 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 13,341 | 66,149 | +395.8% | $2.0M | 2025-Q4 |
| Trexquant Investment LP | DOUBLED | 20,519 | 62,979 | +206.9% | $1.9M | 2025-Q4 |
15 unique insiders with 27 transactions. Net insider value: -$36.5M ($0.00 bought, $36.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | MARAGANORE JOHN | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | Sanchez Ramiro | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | Young Wendy B. | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | Huber Reid M | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | HEALY JAMES | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | Silva Paul M | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | PAUL STEVEN M | Director | AWARD | 15,200 | — | — |
| Jun 10, 2026 | PEREZ ROBERT J | Director | AWARD | 15,200 | — | — |
| May 26, 2026 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 18,572 | $40.05 | $743.8K |
| May 11, 2026 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 133,618 | $40.24 | $5.4M |
| May 8, 2026 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 5,018 | $40.31 | $202.3K |
| May 7, 2026 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 271,495 | $40.12 | $10.9M |
| Apr 17, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 20,225 | $39.99 | $808.8K |
| Apr 17, 2026 | Third Rock Ventures V, L.P. | 10%+ Owner | SELL | 426,005 | $40.32 | $17.2M |
| Apr 14, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 10,200 | $35.08 | $357.8K |
| Apr 13, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 9,165 | $34.97 | $320.5K |
| Apr 10, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 500 | $34.98 | $17.5K |
| Apr 8, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 360 | $34.90 | $12.6K |
| Mar 30, 2026 | Gault Cheryl | Chief Operating Officer | SELL | 7,161 | $28.04 | $200.8K |
| Mar 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | SELL | 10,115 | $29.99 | $303.4K |
| Mar 5, 2026 | Gault Cheryl | Chief Operating Officer | SELL | 2,014 | $28.93 | $58.3K |
| Feb 2, 2026 | Sevigny Jeffrey | Chief Medical Officer | AWARD | 130,000 | — | — |
| Feb 2, 2026 | Bredt David | Chief Scientific Officer | AWARD | 103,000 | — | — |
| Feb 2, 2026 | Ceesay Abraham | Chief Executive Officer | AWARD | 428,000 | — | — |
| Feb 2, 2026 | Ignelzi Troy A. | Chief Financial Officer | AWARD | 148,000 | — | — |
| Feb 2, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | AWARD | 120,000 | — | — |
| Feb 2, 2026 | Gault Cheryl | Chief Operating Officer | AWARD | 132,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 5 neutral. Avg impact: 3.8/10.
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, BlackRock, Fidelity) collectively added $211.6
Jun 11, 2026
BEARISH
144
5/10
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent
May 27, 2026
BEARISH
144
5/10
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 to sell 133,618 shares of Rapport T
May 11, 2026
NEUTRAL
144
3/10
Third Rock Ventures V, L.P., a 10% stockholder, filed Form 144 to sell 5,018 shares of Rapport Thera
May 8, 2026
NEUTRAL
144
3/10
Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 indicating intent to sell 271,495 s
May 7, 2026
MIXED
8-K
6/10
Rapport Therapeutics reported Q1 2026 results with a net loss of $19.9M ($0.42 per share), beating t
May 7, 2026
NEUTRAL
DEFA14A
2/10
Rapport Therapeutics is holding its 2026 Annual Meeting virtually on June 10, 2026, where shareholde
Apr 23, 2026
NEUTRAL
144
3/10
Cheryl Gault, an officer of Rapport Therapeutics, filed a Form 144 to propose the sale of 10,000 sha
Mar 30, 2026
BULLISH
8/10
Rapport Therapeutics announced positive follow-up data from its Phase 2a trial of RAP-219 in focal o
Apr 21, 2026
NEUTRAL
3/10
Rapport Therapeutics announced upcoming presentation of Phase 2a data for its lead candidate RAP-219
Apr 1, 2026
BULLISH
8/10
Rapport Therapeutics reported its 2025 financial results alongside significant clinical and strategi
Mar 10, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$57.10 mean target
+48.7% upside
Strong Buy (1.09)
$40.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $38.40 |
| Target Low | $40.00 |
| Target Mean | $57.10 |
| Target Median | $56.00 |
| Target High | $80.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.09) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.00 | $-1.04 | $-0.90 | -32.9% | -16.6% | 1↑ 4↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-1.00 | $-1.07 | $-0.82 | -40.8% | -5.1% | 2↑ 3↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-3.47 | $-3.67 | $-3.00 | -21.4% | -3.1% | 4↑ 1↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-4.47 | $-5.89 | $-3.56 | -28.7% | -6.4% | 1↑ 4↓ | $0.0B | -100.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.997 | |
| 7d ago | $-0.997 | |
| 30d ago | $-0.855 | -0.142 |
| 60d ago | $-0.855 | -0.142 |
| 90d ago | $-0.832 | -0.165 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 21, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 22, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 11, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Wells Fargo | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
other
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 7, 2026
earnings_calendar
RAPP Q1 2026 Earnings Scheduled — 2026-05-07
Apr 22, 2026
short_interest
FTD: RAPP — 16,400 shares ($0.6M) failed to deliver
Settlement: 20260422, Price: $36.95, FTD Value: $605,980, RAPPORT THERAPEUTICS INC COM
Apr 21, 2026
fda
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
<p align="center"><em>Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical
Apr 17, 2026
short_volume
Short Volume: RAPP — 55.5% short (0.5M / 1.0M)
Short: 531,401 | Exempt: 8,850 | TRF Vol: 958,206 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
earnings
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
<p>BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage
Mar 17, 2026
earnings_calendar
RAPP Q4 2025 Earnings Scheduled — 2026-03-17
Mar 10, 2026
earnings
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 9, 2026
contract
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Mar 9, 2026
earnings_calendar
RAPP Q4 2025 Earnings Scheduled — 2026-03-09
Feb 6, 2026
short_interest
FTD: RAPP — 39,454 shares ($1.0M) failed to deliver
Settlement: 20260206, Price: $25.55, FTD Value: $1,008,049.7, RAPPORT THERAPEUTICS INC COM